SCHEMBL4520486

SCHEMBL4520486

CCOC(=O)c1cc2c(=O)[nH]c(Cc3cccc(C(F)(F)F)c3)nc2s1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.56
TP53 P04637 1/20 0.52
ALDH1A1 P00352 4/20 0.45
HPGD P15428 3/20 0.45
KDM4E B2RXH2 2/20 0.45
GAA P10253 1/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
MAPT P10636 3/20 0.45
HTT P42858 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
MMP1 P03956 1/20 0.41
MMP12 P39900 1/20 0.41
GPR52 Q9Y2T5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3493412 0.87 PDE5A (0.72) PDE5ATP53ALDH1A1KDM4EMEN1
SCHEMBL3491252 0.86 PDE5A (0.61) PDE5AALDH1A1KDM4EMEN1KMT2A
SCHEMBL4515609 0.85 PDE5A (0.76) PDE5AALDH1A1MEN1KMT2AMAPT
SCHEMBL4524427 0.85 TP53 (0.70) TP53ALDH1A1HPGDKDM4EGAA
SCHEMBL16175729 0.82 PDE5A (0.53) PDE5ATP53ALDH1A1MEN1KMT2A
SCHEMBL4522382 0.81 PDE5A (0.57) PDE5AALDH1A1HPGDKDM4EGAA
SCHEMBL21459226 0.80 PDE5A (0.45) PDE5ATP53ALDH1A1MEN1KMT2A
SCHEMBL4511837 0.79 PDE5A (0.50) PDE5AALDH1A1HPGDKDM4EGAA
SCHEMBL4530199 0.79 SMN1; SMN2 (0.50) PDE5AALDH1A1KDM4EMEN1KMT2A
SCHEMBL4520410 0.77 KMT2A (0.66) TP53ALDH1A1HPGDKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 PDE5A 25/4885TP53 2755/4885ALDH1A1 2303/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 PDE5A 25/4885TP53 2755/4885ALDH1A1 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.